BioAtla, Inc. (BCAB) NASDAQ

0.31

-0.0065(-2.07%)

Updated at January 13 04:00PM

Currency In USD

BioAtla, Inc.

Address

11085 Torreyana Road

San Diego, CA 92121

United States of America

Phone

858 558 0708

Sector

Healthcare

Industry

Biotechnology

Employees

61

First IPO Date

December 16, 2020

Key Executives

NameTitlePayYear Born
Jay ShortCo-Founder, Chief Executive Officer & Chairman1.01M1958
Christian VasquezChief Accounting Officer, Controller and Corporate Secretary408,7451975
Richard A. WaldronSenior VP & CFO600,8001954
Eric L. SieversChief Medical Officer637,7751963
Cathy ChangSenior Vice President of Research & Development0N/A
Gerhard FreySenior Vice President of Technology Development0N/A
Lisa PeltonAccounting Manager0N/A
Monica SullivanSenior Vice President of Intellectual Property & Contracts0N/A
Sheri LydickChief Commercial Officer0N/A
Susie MelodySenior Vice President of Human Resources0N/A

Description

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.